Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PDE5A | O76074 | 12/20 | 0.55 |
| ▸ | GUCY1A1 | Q02108 | 6/20 | 0.51 |
| ▸ | GUCY1B1 | Q02153 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19934018 | 0.90 | ADORA3 (0.75) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL19146087 | 0.87 | ADORA3 (0.71) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL173783 | 0.87 | ADORA3 (0.73) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL19147397 | 0.87 | ADORA3 (0.68) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL20148914 | 0.86 | ADORA3 (0.67) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL19019528 | 0.86 | ADORA3 (0.75) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL19019365 | 0.86 | ADORA3 (0.70) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL30507540 | 0.85 | ADORA3 (0.82) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL18212216 | 0.85 | ADORA3 (0.82) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174915 | 0.85 | ADORA3 (0.82) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017103760-A1 | NOVEL POLYMORPH OF RIOCIGUAT AND ITS PROCESS FOR THE PREPARATION | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2017-06-22 | — | — | WO | disclosed |